Article
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Blood advances - 24 Oct 2023
Borate Uma, Yang Fei, Press Richard, Ruppert Amy S, Jones Dan, Caruthers Sean, Zhao Weiqiang, Vergilio Jo-Anne, Pavlick Dean C, Juckett Luke, Norris Brianna, Bucy Taylor, Burd Amy, Stein Eytan M, Patel Prapti, Baer Maria R, Stock Wendy, Schiller Gary, Blum William, Kovacsovics Tibor, Litzow Mark, Foran James, Heerema Nyla A, Rosenberg Leonard, Marcus Sonja, Yocum Ashley, Stefanos Mona, Druker Brian, Byrd John C, Levine Ross L, Mims Alice
Abstract excerpt
Next-generation sequencing (NGS) to identify pathogenic mutations is an integral part of acute myeloid leukemia (AML) therapeutic decision-making. The concordance in identifying pathogenic mutations among different NGS platforms at different diagnostic laboratories has been studied in solid tumors but not in myeloid malignancies to date. To determine this interlaboratory concordance, we collected a total of 194...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.